EPO-TRAUMA Trial

ErythroPOietin alfa to prevent mortality and reduce severe disability in critically ill TRAUMA patients: a multi-centre, stratified, double-blind, randomised, placebo-controlled trial. (The EPO-TRAUMA trial)

ErythroPOietin alfa to prevent mortality and reduce severe disability in critically ill TRAUMA patients

Sites32
Patients813

Committee
Contacts
Progress

Study Progress

Country	Recruited
Australia	450
New Zealand	159
Finland	66
Switzerland	59
Saudi Arabia	43
Ireland	29
Slovenia	7
Total	813